Maggie Taylor Davis, PhD
Associate Professor of PsychiatryCards
Appointments
Psychiatry
Primary
Department of Psychology
Secondary
Contact Info
About
Titles
Associate Professor of Psychiatry
Biography
Dr. Davis is a licensed clinical psychologist and Assistant Professor in the Yale Department of Psychiatry. In July 2018 she completed a T32 funded postdoctoral fellowship (Yale Neuroimaging Sciences Training Program) under the mentorship of Dr. Irina Esterlis, and transitioned to faculty status after obtaining an NIMH funded K08 award. Her research interests center on use of molecular neuroimaging methods to enhance understanding of the relationship between suicidal behavior and stress-related psychopathology. Under her K08 award, she is investigating the relationship between availability of mGluR5 (a mostly postsynaptic glutamate receptor involved in the regulation of emotion and pain experience), borderline personality disorder (BPD) symptom presentation, and suicidal behavior. Dr. Davis is also completing a study examining in vivo kappa opioid receptor availability in BPD, and its relationship to history of suicidal behavior. Ultimately, she hopes to build of this study and similar work to craft independent lines of research investigating molecular mechanisms subserving stress-related pathology (e.g., BPD, PTSD, eating disordered behavior) and suicidal behavior in service of novel, targeted treatment development
Appointments
Psychiatry
Associate Professor on TermPrimaryDepartment of Psychology
Assistant ProfessorSecondary
Other Departments & Organizations
- Department of Psychology
- Janeway Society
- MR Center
- Psychiatry
- Translational Brain Imaging Program
- Yale Instruction/Investigation/Intervention in Emotional Lability and Dysregulation (YIELD)
Education & Training
- Postdoctoral Fellow
- Yale University School of Medicine (2018)
- Predoctoral Intern
- University of Michigan/ VA Ann Arbor Healthcare System (2016)
- PhD
- Auburn University, Clinical Psychology (2016)
- MS
- Auburn University, Clinical Psychology (2013)
- BA
- University of Virginia, Psychology (2006)
Research
Overview
Medical Research Interests
Behavior and Behavior Mechanisms; Borderline Personality Disorder; Feeding and Eating Disorders; Functional Neuroimaging; Mental Disorders; Pain; Positron-Emission Tomography; Psychiatry and Psychology; Stress Disorders, Post-Traumatic; Suicide; Trauma and Stressor Related Disorders
Public Health Interests
Mental Health; Substance Use, Addiction
- View Lab Website
Yale Translational Brain Imaging Lab
Research at a Glance
Yale Co-Authors
Frequent collaborators of Maggie Taylor Davis's published research.
Publications Timeline
A big-picture view of Maggie Taylor Davis's research output by year.
Research Interests
Research topics Maggie Taylor Davis is interested in exploring.
Irina Esterlis, PhD
John Krystal, MD
Nabeel Nabulsi, PhD
Richard Carson, PhD
David Matuskey, MD
Nicole DellaGioia
39Publications
4,985Citations
Stress Disorders, Post-Traumatic
Positron-Emission Tomography
Suicide
Mental Disorders
Borderline Personality Disorder
Trauma and Stressor Related Disorders
Publications
2024
An in vivo examination of the relationship between metabotropic glutamate receptor 5 and suicide attempts in people with borderline personality disorder
Davis M, Asch R, Weiss E, Wagner A, Fineberg S, Nabulsi N, Matuskey D, Carson R, Esterlis I. An in vivo examination of the relationship between metabotropic glutamate receptor 5 and suicide attempts in people with borderline personality disorder. Biological Psychiatry Cognitive Neuroscience And Neuroimaging 2024 PMID: 39613160, DOI: 10.1016/j.bpsc.2024.11.014.Peer-Reviewed Original ResearchConceptsBorderline personality disorderPathophysiology of borderline personality disorderSuicide attemptsPersonality disorderPositron emission tomographyAssociated with history of suicide attemptBorderline personality disorder symptomsBPD pathophysiologyPositron emission tomography outcomes measurementsHistory of suicide attemptsMetabotropic glutamate receptor type 5Metabotropic glutamate receptor 5Glutamate receptor 5Comprehensive clinical assessmentFrontolimbic circuitsMDD groupDepressive disorderEmotion regulationPsychiatric conditionsCognitive functionMGlu5Comparison controlsMDDSuicideAssociated with historyMetabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use
Weiss E, Davis M, Asch R, D'Souza D, Cool R, Esterlis I. Metabotropic Glutamate Receptor 5 as a Potential Biomarker of the Intersection of Trauma and Cannabis Use. The International Journal Of Neuropsychopharmacology 2024, 27: pyae044. PMID: 39320043, DOI: 10.1093/ijnp/pyae044.Peer-Reviewed Original ResearchAltmetricConceptsTrauma-related psychopathologyCannabis useDepressive symptomsPositron emission tomographyCross-diagnostic sampleMetabotropic glutamate receptor 5Treatment development effortsAssociated with depressive symptomsGlutamate receptor 5CU groupSample of individualsAvailability in vivoFrontolimbic regionsGlutamatergic systemGlutamatergic neurotransmissionMGlu5PsychopathologyReceptor 5Intersection of traumaExploratory analysisCannabisEmission tomographySymptomsParticipantsVmPFCMicroglia-mediated neuroimmune suppression in PTSD is associated with anhedonia
Bonomi R, Hillmer A, Woodcock E, Bhatt S, Rusowicz A, Angarita G, Carson R, Davis M, Esterlis I, Nabulsi N, Huang Y, Krystal J, Pietrzak R, Cosgrove K. Microglia-mediated neuroimmune suppression in PTSD is associated with anhedonia. Proceedings Of The National Academy Of Sciences Of The United States Of America 2024, 121: e2406005121. PMID: 39172786, PMCID: PMC11363315, DOI: 10.1073/pnas.2406005121.Peer-Reviewed Original ResearchCitationsMeSH Keywords and ConceptsConceptsPTSD groupPrefrontal-limbic circuitsNeuroimmune responseAssociated with anhedoniaPosttraumatic stress disorderPositron emission tomography brain imagingTranslocator protein availabilityBrain immune functionAnhedonic symptomsStress disorderPeripheral immune dysfunctionPTSDGroup differencesSeverity of symptomsPsychiatric diseasesTranslocator proteinBrain imagingAdministration of lipopolysaccharideSymptomsMicroglial markersLPS-induced increaseCompared to controlsImmune functionSickness symptomsAnhedoniaW35 Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders
Baldassarri S, Asch R, Hillmer A, Pietrzak R, DellaGioia N, Esterlis I, Davis M. W35 Nicotine Use and Metabotropic Glutamate Receptor 5 (mGluR5) in Individuals With Major Depressive and Post Traumatic Stress Disorders. Drug And Alcohol Dependence 2024, 260: 110653. DOI: 10.1016/j.drugalcdep.2023.110653.Peer-Reviewed Original ResearchDeficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder
Asch R, Worhunsky P, Davis M, Holmes S, Cool R, Boster S, Carson R, Blumberg H, Esterlis I. Deficits in prefrontal metabotropic glutamate receptor 5 are associated with functional alterations during emotional processing in bipolar disorder. Journal Of Affective Disorders 2024, 361: 415-424. PMID: 38876317, PMCID: PMC11250898, DOI: 10.1016/j.jad.2024.06.025.Peer-Reviewed Original ResearchCitationsConceptsMetabotropic glutamate receptor 5Bipolar disorderGlutamate receptor 5Positron emission tomographyFear processingEmotional processingAssociated with greater activationEmotion processing taskAssociated with impulsivityFunctional brain differencesAssociated with functional alterationsParietal brain regionsPathology of BDIncreased cortical activityAssociated with difficultiesDepressive disorderHealthy comparisonReceptor availabilityBrain differencesPre/postcentral gyriAttention difficultiesGreater activationBrain regionsPsychomotor functionTreatment developmentPost-traumatic change and resilience after childhood maltreatment: Impacts on maternal mental health over the postpartum period
Armer J, Oh W, Davis M, Issa M, Sexton M, Muzik M. Post-traumatic change and resilience after childhood maltreatment: Impacts on maternal mental health over the postpartum period. Journal Of Affective Disorders 2024, 361: 1-9. PMID: 38844162, DOI: 10.1016/j.jad.2024.06.010.Peer-Reviewed Original ResearchCitationsConceptsPostpartum mental healthLow symptom classMental health symptomsMental health trajectoriesChildhood maltreatmentMental healthHealth trajectoriesHealth symptomsPost-traumatic changesAssociated with reduced psychopathologyHistory of childhood maltreatmentMaternal mental healthMental health classesPost-traumatic cognitionsMental health changesAdverse postpartum outcomesPost-traumatic growthIdentification of mothersHigh-risk classMultinomial logistic regression modelLogistic regression modelsChronic high riskGeneralizability of findingsInterview measuresHealth changesPreliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders
Fan S, Asch R, Davis M, DellaGioia N, Cool R, Blumberg H, Esterlis I. Preliminary Study of White Matter Abnormalities and Associations With the Metabotropic Glutamate Receptor 5 to Distinguish Bipolar and Major Depressive Disorders. Chronic Stress 2024, 8: 24705470231225320. PMID: 38250007, PMCID: PMC10798116, DOI: 10.1177/24705470231225320.Peer-Reviewed Original ResearchCitationsAltmetricConceptsMetabotropic glutamate receptor 5Bipolar disorderGlutamate receptor 5UF FAUncinate fasciculusFractional anisotropyWhole-brain analysisMultimodal neuroimaging approachDifferentiation of BDDiffusion-weighted MRI scansFrontotemporal dysconnectivityFrontotemporal systemFunctional dysconnectivityDepressive disorderNeurobiological mechanismsMGluR5 levelsWhite matterWhite matter abnormalitiesNeuroimaging approachesWM integrityNeural mechanismsMDDWhole-brainWM abnormalitiesReceptor 5Differences in Diagnostic Rules Used to Determine Borderline Personality Disorder Impact Prevalence and Associations with Clinically Relevant Variables: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III
Loya J, Wagner A, Pittman B, Davis M. Differences in Diagnostic Rules Used to Determine Borderline Personality Disorder Impact Prevalence and Associations with Clinically Relevant Variables: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions-III. Personality Disorders Theory Research And Treatment 2024, 15: 60-73. PMID: 38206863, PMCID: PMC10786338, DOI: 10.1037/per0000643.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsBorderline personality disorderBorderline personality disorder diagnosisPrevalence of borderline personality disorderBorderline personality disorder statusClinically relevant variablesNational Epidemiologic SurveyRelated Conditions-IIIMental health conditionsGeneralizability of findingsPersonality disorderClinical interviewClinical variablesProblem behaviorsDisorder prevalenceConditions-IIIRelevant variablesMethodological differencesEpidemiological surveyDisordersBorderlineDiagnostic rulesPrevalence ratesU.S. adultsHealth consequencesHealth conditions
2020
Exploring the impact of trauma type and extent of exposure on posttraumatic alterations in 5-HT1A expression.
Lewis MW, Jones RT, Davis MT. Exploring the impact of trauma type and extent of exposure on posttraumatic alterations in 5-HT1A expression. Translational Psychiatry 2020, 10: 237. PMID: 32678079, PMCID: PMC7366706, DOI: 10.1038/s41398-020-00915-1.Peer-Reviewed Original ResearchExploring the impact of trauma type and extent of exposure on posttraumatic alterations in 5-HT1A expression
Lewis M, Jones R, Davis M. Exploring the impact of trauma type and extent of exposure on posttraumatic alterations in 5-HT1A expression. Translational Psychiatry 2020, 10: 237. PMID: 32678079, PMCID: PMC7366706, DOI: 10.1038/s41398-020-00915-1.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and ConceptsConceptsTrauma typesTrauma exposureImpact of trauma typeExposure to potentially traumatic eventsSerotonin 1 A receptorExpression of 5-HT1AImpact of trauma exposureTrauma-exposed individualsRegulating serotonin releasePotentially traumatic eventsG protein-coupled serotonin receptorsImpact of traumaNeurobiological impactNeurobiological effectsHTR1A genePsychiatric syndromesEmotional behaviorPsychiatric symptomsStress respondingSerotonin receptorsTraumatic eventsSerotonin releaseExtent of exposureHuman literatureTrauma-induced changes
Clinical Trials
Current Trials
Eligibility for Participation in Neuroimaging Studies
HIC ID2000027842RoleSub InvestigatorPrimary Completion Date12/31/2023Recruiting ParticipantsDysregulation in mGluR5 as a marker of BPD and suicide related endophenotypes
HIC ID2000023168RolePrincipal InvestigatorPrimary Completion Date10/31/2023Recruiting ParticipantsGenderBothAge18 years - 65 yearsAMPA Receptor Components of the Anti-Depressant Ketamine Response
HIC ID2000021345RoleSub InvestigatorPrimary Completion Date06/30/2032Recruiting ParticipantsGenderBothAge18 years - 65 yearsImaging mGluR5 and synaptic density in psychiatric disorders
HIC ID2000020186RoleSub InvestigatorPrimary Completion Date01/31/2018Recruiting ParticipantsGenderBothAge18 years - 80 years
Academic Achievements & Community Involvement
honor Patterson Trust Mentored Research Award
Regional AwardRobert Leet and Clara Guthrie Patterson TrustDetails02/28/2021United Stateshonor Loan Repayment Award (Clinical Research)
National AwardNIMHDetails11/01/2019United Stateshonor Early Career Investigator Travel Fellowship Award
National AwardSociety for Biological PsychiatryDetails05/17/2019United Stateshonor Yale Clinical Neuroimaging Conference Poster/ Presentation Award
Yale School of Medicine AwardYale UniversityDetails02/14/2017United States
News
News
- August 23, 2024
Microglia-Mediated Neuroimmune Suppression in PTSD Is Associated With Anhedonia
- February 23, 2021
Davis Chosen to Give Rising Star Showcase Presentation
- November 20, 2019
Yale Researchers Measure Ketamine's Effects on a Glutamate Receptor
- May 14, 2019
Biomarker Reveals PTSD Sufferers at Risk of Suicide
Get In Touch
Contacts
Office Fax Number